比较5天与10天方案地西他滨治疗老年新诊断急性髓系白血病的随机2期试验
该随机2期试验纳入71例老年新诊断急性髓系白血病患者,比较5天与10天地西他滨方案的疗效与安全性。5天组28例、10天组43例,复合主要终点(完全缓解、CRp、CRi)达成率相似(43% vs 40%,p=0.78)。两组总生存、不良事件及早期死亡率均无显著差异。
要点
- 5天与10天地西他滨方案在老年新诊断AML中疗效相似,复合缓解率43% vs 40%(p=0.78)。
- 两组中位总生存分别为5.5个月与6.0个月,1年总生存率均为25%。
- 3-4级不良事件以中性粒细胞缺乏伴发热和感染最常见,两组早期死亡率相似。
核心结论
- 在老年新诊断急性髓系白血病患者中,5天与10天地西他滨方案的疗效和安全性无差异。
研究设计与样本
- 随机2期试验,纳入≥60岁不适合强化化疗的新诊断急性髓系白血病患者(或<60岁但不适合蒽环类联合阿糖胞苷强化化疗者)。
- 前40例按计算机生成区组随机(区组大小40)等额分配至两组,之后采用反应适应性随机算法根据既往患者治疗和反应数据分配后续患者。
- 地西他滨20 mg/m2静脉注射,连续5天或10天作为诱导治疗,每4-8周一次,最多3个周期;缓解者接受5天方案地西他滨巩固治疗,最多24个周期。
- 主要终点为任意时间达到的完全缓解、完全缓解伴血小板未完全恢复(CRp)和完全缓解伴血液学未完全恢复(CRi)的复合终点,按意向治疗分析。
- 试验注册号ClinicalTrials.gov NCT01786343。
主要发现
- 2013年2月28日至2018年4月12日共入组71例,5天组28例、10天组43例,全部可评估疗效和安全性。
- 主要终点达成率:5天组12/28(43%,95%可信区间26-60),10天组17/43(40%,26-54),p=0.78,差异3%(-21至27)。
- 总随访38.2个月,中位总生存:5天组5.5个月(IQR 2.1-11.7),10天组6.0个月(1.9-11.7);1年总生存率两组均为25%。
- 按细胞遗传学、新发 vs 继发/治疗相关急性髓系白血病或TP53mut状态分层,完全缓解、CRp、CRi和总生存两组均无差异。
- 最常见3-4级不良事件:中性粒细胞缺乏伴发热5天组7例(25%)vs 10天组14例(33%);感染5天组5例(18%)vs 10天组16例(37%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypomethylating agents, such as decitabine, are the standard of care for older patients with newly diagnosed acute myeloid leukaemia. Single-arm studies have suggested that a 10-day schedule of decitabine cycles leads to better outcomes than the usual 5-day schedule. We compared the efficacy and safety of these two schedules. METHODS: Eligible patients were aged 60 years or older with acute myeloid leukaemia but unsuitable for intensive chemotherapy (or <60 years if unsuitable for intensive chemotherapy with an anthracycline plus cytarabine). The first 40 patients were allocated equally to the two treatment groups by computer-generated block randomisation (block size 40), after which a response-adaptive randomisation algorithm used all previous patients' treatment and response data to decide the allocation of each following patient favouring the group with superior response. Patients were assigned to receive 20 mg/m2 decitabine intravenously for 5 or 10 consecutive days as induction therapy, every 4-8 weeks for up to three cycles. Responding patients received decitabine as consolidation therapy on a 5-day schedule for up to 24 cycles. We assessed a composite primary endpoint of complete remission, complete remission with incomplete platelet recovery (CRp), and complete remission with incomplete haematological recovery (CRi) achieved at any time and assessed by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01786343. FINDINGS: Between Feb 28, 2013, and April 12, 2018, 71 patients were enrolled. 28 received decitabine for 5 days and 43 for 10 days, and all were assessable for efficacy and safety. The primary endpoint was achieved in similar proportions of patients in the two treatment groups (12 [43%] of 28 in the 5-day schedule group, 95% credible interval 26-60, and 17 [40%] of 43 in the 10-day schedule group, 26-54, p=0·78; difference 3%, -21 to 27). Total follow-up was 38·2 months, during which the median duration of overall survival was 5·5 months (IQR 2·1-11·7) in the 5-day group and 6·0 months (1·9-11·7) in the 10-day group. 1-year overall survival was 25% in both groups. Complete remission, CRp, CRi, and overall survival did not differ between groups when stratified by cytogenetics, de-novo versus secondary or therapy-related acute myeloid leukaemia, or TP53mut status. The most common grade 3-4 adverse events were neutropenic fever (seven patients [25%] in the 5-day group and 14 [33%] in the 10-day group) and infection (five [18%] and 16 [37%], respectively). One patient (4%) died from sepsis in the context of neutropenic fever, infection, and haemorrhage in the 5-day group, and in the 10-day group six patients (14%) died from infection. Early mortality was similar in the two groups. INTERPRETATION: In older patients with newly diagnosed acute myeloid leukaemia, efficacy and safety did not differ by the 5-day or the 10-day decitabine schedule. FUNDING: University of Texas MD Anderson Cancer Center and National Cancer Institute Specialized Programs of Research Excellence.
引用
- Short NJ, Kantarjian HM, Loghavi S, et al. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol. 2018. PMID: 30545576. doi:10.1016/S2352-3026(18)30182-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。